Safety/Effacy Clinical Trial
Official title:
A Phase IV, Open-label, Parallel Group, Single-Center Study on the Effects of a Nutritional Supplement Combination on Body Weight Management Over a 90-day Period
| Verified date | November 2012 |
| Source | Pharmanex |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Food and Drug Administration |
| Study type | Interventional |
Title: A Phase IV, Open-label, Single-Center Study on the Effects of a Nutritional Supplement Combination on Body Weight Management over a 90-day period
| Status | Completed |
| Enrollment | 60 |
| Est. completion date | October 2014 |
| Est. primary completion date | October 2014 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 25 Years to 65 Years |
| Eligibility |
Inclusion Criteria: 1. Females and Males aged 25-65 years 2. Signed informed consent 3. BMI between 25 and 40 kg/m2 4. A resting normotensive blood pressure is defined as a systolic blood pressure between 90-145 mmHg and a diastolic blood pressure of 50 90 mmHg 5. Use of effective method of contraception by females of childbearing [potential and agreement to continue to practice an acceptable method of contraception for the duration of their participation in the study]. Acceptable methods of contraception include oral, injectable, or implantable contraceptives; intrauterine devices, diaphragm plus spermicide; abstinence (must agree to use double-barrier method if they become sexually active), transdermal patch, or any double barrier method including a vasectomized sexual partner. Women who have had a hysterectomy or tubal ligation at least 6 months prior to Visit 1 or who have been post-menopausal 6. Ability to speak and understand English 7. Willing to fast the morning of visit where blood samples are taken Exclusion Criteria: 1. Self-reported chronic condition that may affect subject safety (e.g., diabetes, cardiovascular disease) or significantly impact product effectiveness (e.g., chronic fatigue) 2. Pregnancy/suspected pregnancy, breastfeeding or planning to become pregnant during the course of the study. 3. Use of Antihypertensive medication for less than 4 months or unregulated clinically blood pressure. 4. Having undergone gastroplasty or bariatric surgery in the past 10 years. 5. Taking medication (e.g., thyroid medication), must be stable for at least four months. 6. Allergies to any ingredients contained in the Nutritional Supplement. 7. Medical treatment for insomnia or depression within 30-days prior to the screening visit. 8. Tobacco (e.g. cigarettes, chewing tobacco, pipe, nicotine patches) use within 30-days prior to the screening visit. 9. Planned surgical procedure during the course of the study. 10. Currently participating in another study or have done so within 30 days prior to the screening visit or is likely to enroll in another clinical or nutritional study. 11. Currently taking any medication or supplement for the use of weight loss must be discontinued prior to Visit 1 Baseline Day 0. 12. Currently participating in a weight loss program or participated in a weight loss program in the past 6 months. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United States | Aspen Clinical Research | Orem | Utah |
| Lead Sponsor | Collaborator |
|---|---|
| Pharmanex | Nu Skin Enterprises |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | -Evaluate the changes in body composition as determined by percent body fat using the Bod Pod | 90 Days | Yes | |
| Secondary | Evaluate the changes in body weight | Determine the safety and tolerability of a weight loss system and dietary supplements containing ingredients to promote healthy weight Evaluate the changes in body weight as measured by body weight and body composition changes (as determined by BMI as well as changes in body measurements-waist, hip, arm, and ankle circumferences) of a weight loss system and dietary supplements containing ingredients to promote healthy weight. Determine changes in substrate energy utilization Determine subjective measurements of hunger, appetite, feeling of well being during weight loss Determine changes in expansion and return of blood vessels (pulse wave analyzer) |
90 days | No |